Pro­tag­o­nist aborts lead ul­cer­a­tive col­i­tis pro­gram af­ter drug fiz­zles in PhI­Ib, stock craters

8 years ago
R&D

Gain­ing steam in PD-1/L1 race, Roche re­ports pos­i­tive PhI­II OS da­ta on Tecen­triq com­bo in NSCLC

8 years ago
R&D

Failed again: Sanofi's Abl­ynx re­ports PhII lu­pus flop

8 years ago
R&D

Beat­ing out mar­ket lead­ers in PhII, an­tibi­ot­ic-mak­er Al­le­cra read­ies for Phase III tri­als

8 years ago
R&D

With ma­jor fund­ing from No­var­tis, Sur­face On­col­o­gy launch­es a CD47 tri­al amid a swarm of ri­vals and files for $75M ...

8 years ago
Financing
Startups

Helsinn buys glob­al rights for skin can­cer drug from Acte­lion; Ake­bia reels in more cash for vadadu­s­tat; EMA slams ...

8 years ago
News Briefing

Backed in part by Roche, Den­mark's NMD gets $47M to run or­phan neu­ro­mus­cu­lar dis­ease tri­als

8 years ago
Financing
Startups

Di­rec­tor of di­ver­si­ty and in­clu­sion ar­rives at Mass­Bio; Jerome Jab­bour takes the helm at Mati­nas; Ex-Eli Lil­ly CFO ...

8 years ago
Peer Review

Con­gress ap­proves gov­ern­ment spend­ing bill with in­creased FDA fund­ing

8 years ago
Pharma

GSK drops out of $20B race for Pfiz­er's con­sumer health unit — shares surge

8 years ago
R&D

In a blow to its biggest rev­enue dri­ver, In­di­v­ior los­es patent bat­tle with gener­ics mak­er Alvo­gen

8 years ago
Pharma

Mor­phoSys files for $150M IPO to fu­el its hope­ful DL­B­CL drug launch

8 years ago
Financing

Poised for an FDA pitch, No­var­tis lays out all its PhI­II cards on MS drug sipon­i­mod

8 years ago
R&D

An­oth­er im­munome­tab­o­lism deal? Johns Hop­kins spin­out Dra­cen lands $36M in­vest­ment from Deer­field

8 years ago
Financing

Uni­corn Mod­er­na joins line­up to list on Hong Kong's ex­change; Proces­sa li­cens­es com­pound from Con­cert

8 years ago
News Briefing

No­vo Nordisk's pick for new chair­man sig­nals its on­go­ing pur­suit of M&A deals

8 years ago
People
Deals

Ab­b­Vie shares tank on Ro­va-T flop, sud­den re­treat from ac­cel­er­at­ed ap­proval pitch

8 years ago
R&D

Sun Phar­ma screech­es to the pso­ri­a­sis fin­ish line with FDA OK of Ilumya. Too bad ri­vals J&J and oth­ers beat them to ...

8 years ago
Pharma

Third Rock de­buts im­munome­tab­o­lism start­up Rheos with $60M launch round

8 years ago
Financing
Startups

House Re­pub­li­cans mount a suc­cess­ful come­back cam­paign for right-to-try bill

8 years ago
Pharma

Cash­ing in on PhII tri­al suc­cess, Are­na to raise $353M to fu­el PhI­II etrasi­mod/ra­linepag tri­als

8 years ago
R&D

12 block­busters: The surg­ing list of $1B-plus drugs rolling out on the mar­ket this year might sur­prise you

8 years ago
R&D
Special

The PC­SK9 of NASH? Re­gen­eron and Al­ny­lam join forces to tack­le a promis­ing tar­get for se­vere liv­er dis­eases

8 years ago
Discovery

Pro­teosta­sis pulls stock of­fer­ing fol­low­ing Ker­ris­dale short re­port; Cidara is­sues sup­ple­men­tal PhII reza­fun­gin da­ta

8 years ago
News Briefing
First page Previous page 1064106510661067106810691070 Next page Last page
A service from the Financial Times